中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
24期
28-32
,共5页
安慰剂%雌二醇屈螺酮%绝经后心悸症状%雌激素疗法
安慰劑%雌二醇屈螺酮%絕經後心悸癥狀%雌激素療法
안위제%자이순굴라동%절경후심계증상%자격소요법
Placebos%Symptoms among postmenopausal%Estradiol drospirenone%Hormone therapy
目的 评价雌二醇屈螺酮治疗绝经后心悸症状的疗效.方法 通过检索PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊全文数据库,对纳入研究的方法学进行评价.研究者对纳入文献的质量进行严格评价和资料提取,使用Review manager 5.0软件对符合质量标准的随机分组对照临床试验(RCT)行系统评价.结果 13个RCT共纳入1 156例患者,其中治疗组650例,对照组506例,系统评价结果显示:采用雌二醇屈螺酮治疗绝经后心悸症状,相对雌激素替代疗法能显著提升疗效[相对危险度(RR)=-11.89、95％可信区间(95％ CI)-13.06～-10.72],相对安慰剂疗法能显著提升疗效(RR=-12.99、95％ CI-14.46 ～-11.52).结论 雌二醇屈螺酮可显著改善绝经后心悸症状,值得推广.
目的 評價雌二醇屈螺酮治療絕經後心悸癥狀的療效.方法 通過檢索PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中國學術期刊全文數據庫、萬方數據庫、維普中文科技期刊全文數據庫,對納入研究的方法學進行評價.研究者對納入文獻的質量進行嚴格評價和資料提取,使用Review manager 5.0軟件對符閤質量標準的隨機分組對照臨床試驗(RCT)行繫統評價.結果 13箇RCT共納入1 156例患者,其中治療組650例,對照組506例,繫統評價結果顯示:採用雌二醇屈螺酮治療絕經後心悸癥狀,相對雌激素替代療法能顯著提升療效[相對危險度(RR)=-11.89、95％可信區間(95％ CI)-13.06～-10.72],相對安慰劑療法能顯著提升療效(RR=-12.99、95％ CI-14.46 ～-11.52).結論 雌二醇屈螺酮可顯著改善絕經後心悸癥狀,值得推廣.
목적 평개자이순굴라동치료절경후심계증상적료효.방법 통과검색PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、중국학술기간전문수거고、만방수거고、유보중문과기기간전문수거고,대납입연구적방법학진행평개.연구자대납입문헌적질량진행엄격평개화자료제취,사용Review manager 5.0연건대부합질량표준적수궤분조대조림상시험(RCT)행계통평개.결과 13개RCT공납입1 156례환자,기중치료조650례,대조조506례,계통평개결과현시:채용자이순굴라동치료절경후심계증상,상대자격소체대요법능현저제승료효[상대위험도(RR)=-11.89、95％가신구간(95％ CI)-13.06～-10.72],상대안위제요법능현저제승료효(RR=-12.99、95％ CI-14.46 ～-11.52).결론 자이순굴라동가현저개선절경후심계증상,치득추엄.
Objective To evaluate the efficacy of estradiol drospirenone treatment on palpitation in postmenopausal women.Methods Retrieved nearly a decade PubMed,Science Direct,EBSCO Host,EMbase,The Cochrane Library,CNKI,Wanfang database,CQVIP.The evaluation methodology included.The researchers rigorously evaluated he quality of the included studies and extracted data,used the Review manager 5.0 software to meet the quality standards of randomized controlled clinical trials (RCT) line system evaluation.Results Thirteen RCTs were included 1 156 patients,506 cases in the control group,650 patients in the treatment group.The results of the evaluation of the system showed:estradiol drospirenone treatment could significantly improve the efficacy of postmenopausal symptoms,compared with hormone therapy [relative risk (RR) =-11.89,95％ confidence interval (95 ％ CI)-13.06--10.72],versus placebo therapy (RR =-12.99,95％CI-14.46--11.52).Conclusion Estradiol drospirenone can significantly enhance the efficacy of postmenopausal symptoms,be worthy of promotion.
